The primary and secondary cellular immune responses to whole cell Bordetella pertussis vaccine and its components
- PMID: 3498569
- PMCID: PMC1542715
The primary and secondary cellular immune responses to whole cell Bordetella pertussis vaccine and its components
Abstract
The cellular immune responses of Balb/c mice and Wistar rats immunized in hind footpads with intact killed Bordetella pertussis were found to differ from those of similar animals immunized with other bacteria including Bordetella bronchiseptica, Salmonella typhimurium and Escherichia coli. All the bacteria stimulated increases in cell number, proliferation and interleukin 2 (IL-2) production in popliteal lymph nodes which peaked 3-5 days after injection and decreased to resting levels by day 7. However, B. pertussis also caused a second peak in all three parameters at 11 days after immunization. This peak was not seen following injection with any of the other bacteria. Bordetella pertussis also caused systemic effects, increased cellular proliferation in bone marrow and thymus, with similar biphasic kinetics. It possesses a potent toxin, distinguishing it from the closely related B. bronchiseptica. The use of purified materials confirmed that the presence of this pertussis toxin (PT) was responsible for the later peak in stimulation, whereas lipopolysaccharide (LPS) in combination with PT and also the filamentous haemagglutinin (FHA) could mimic the early peak of stimulation. Primary immunization with B. pertussis was also shown to generate lymph node cells which responded in vitro to secondary challenge with B. pertussis cells, FHA or PT. Both proliferation and IL-2 production were enhanced, except with FHA which only increased IL-2 production. Lymph node cells from mice immunized with E. coli showed no such responses.
Similar articles
-
Human cellular immune responses to Bordetella pertussis infection.FEMS Microbiol Immunol. 1989 Mar;1(4):205-11. doi: 10.1111/j.1574-6968.1989.tb02384.x. FEMS Microbiol Immunol. 1989. PMID: 2629905
-
Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice.Vaccine. 2012 Aug 31;30(40):5864-70. doi: 10.1016/j.vaccine.2012.07.005. Epub 2012 Jul 17. Vaccine. 2012. PMID: 22814407
-
Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.Clin Exp Immunol. 2006 Jun;144(3):543-51. doi: 10.1111/j.1365-2249.2006.03097.x. Clin Exp Immunol. 2006. PMID: 16734625 Free PMC article.
-
Human T-cell immunity against Bordetella pertussis analyzed at clonal level.Tokai J Exp Clin Med. 1988;13 Suppl:253-7. Tokai J Exp Clin Med. 1988. PMID: 2908527
-
Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice.Clin Exp Immunol. 2005 Jul;141(1):37-46. doi: 10.1111/j.1365-2249.2005.02807.x. Clin Exp Immunol. 2005. PMID: 15958068 Free PMC article.
Cited by
-
Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis.Infect Immun. 1992 Nov;60(11):4563-70. doi: 10.1128/iai.60.11.4563-4570.1992. Infect Immun. 1992. PMID: 1398968 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources